Russia: Serialization and Aggregation of Medications Becoming Mandatory.

July 10, 2019

Counterfeit products naturally pose a major problem in the pharmaceutical sector. This affects brand-name and generic products as well as OTC (over the counter) products. Counterfeiters not only bring imitation medication into circulation through non-authorized pharmacies and online portals, but also successfully plant them in the legal distribution chain via wholesalers and the pharmacy network.

Spotlight

Burrard Pharmaceuticals

Burrard Pharmaceuticals is an international leading biopharmaceutical company. We have access to modern state-of-the-art pharmaceutical facilities. The operational efficiency of our facility results in diverse production options, reduced lifecycle costs and compliance to all pharma GMP regulations. We have extensive expert resources combining unique processes and full technology integration. Since our founding in 2005, we are at the forefront of drug manufacturing and technology transfer.

OTHER WHITEPAPERS
news image

Effects Of X-Ray Inspection On Pharmaceutical Products

whitePaper | December 12, 2019

X-ray inspection of pharmaceutical products and over-the-counter (OTC) medications are steadily increasing in use as pharmaceutical manufacturers worldwide strive to safeguard their brand reputations, protect consumers' welfare and comply with national and international regulations and legislation.

Read More
news image

Pharmaceutical Sales Strategies Post-COVID-19: The Benefits of Virtual Engagement

whitePaper | April 7, 2021

In less than a week, in the face of a pandemic, the pharmaceutical sales model changed forever. In-person healthcare provider (HCP) visits came to a screeching halt and brand marketers scrambled to find ways to educate and engage these providers remotely. While the pandemic may have taken us by surprise, we should acknowledge that, even before the pandemic, pharmaceutical sales teams faced significant challenges. One solution for these challenges is to engage HCPs – virtually.

Read More
news image

Defragmenting Data for the Future of Pharma R&D

whitePaper | November 7, 2019

This in-depth paper will show you how to become data agile – tackling both technological issues and solutions, and the cultural and strategic framework needed around this to ensure success.

Read More
news image

Prescription Drug Pricing: How Lack of Transparency Reduces Market Access, Utilization, and Adherence

whitePaper | November 25, 2019

It's clear that healthcare prices weigh heavily on the minds of Americans, and the time has come for the pharmaceutical industry to take the reins of the prescription drug pricing dialogue with consumers.

Read More
news image

Coronavirus (COVID-19) and Its Effect on Pharmaceutical Marketing and Sales

whitePaper | March 16, 2020

With the rapid onset of coronavirus in the United States, many pharma companies are being forced to prepare for a scenario in which their reps cannot visit providers and patients are limited in their ability to visit their healthcare professionals (HCP). The CDC has gone as far as recommending the use of telemedicine and patient portals as primary channels for HCPs and patients to interact.

Read More
news image

Research and Development in the Pharmaceutical Industry

whitePaper | April 1, 2021

Every year, the U.S. pharmaceutical industry develops a variety of new drugs that provide valuable medical benefits. Many of those drugs are expensive and contribute to rising health care costs for the private sector and the federal government. Policymakers have considered policies that would lower drug prices and reduce federal drug expenditures. Such policies would probably reduce the industry’s incentive to develop new drugs.

Read More

Spotlight

Burrard Pharmaceuticals

Burrard Pharmaceuticals is an international leading biopharmaceutical company. We have access to modern state-of-the-art pharmaceutical facilities. The operational efficiency of our facility results in diverse production options, reduced lifecycle costs and compliance to all pharma GMP regulations. We have extensive expert resources combining unique processes and full technology integration. Since our founding in 2005, we are at the forefront of drug manufacturing and technology transfer.

Events